BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143:155-72. [PMID: 30194992 DOI: 10.1016/j.jaci.2018.08.022] [Cited by in Crossref: 176] [Cited by in F6Publishing: 151] [Article Influence: 44.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu J, Guttman-yassky E. Efficacy of biologics in atopic dermatitis. Expert Opinion on Biological Therapy 2020;20:525-38. [DOI: 10.1080/14712598.2020.1722998] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
2 Qi HJ, Li LF. New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration. Biomed Res Int 2021;2021:5528372. [PMID: 34195265 DOI: 10.1155/2021/5528372] [Reference Citation Analysis]
3 De Bruyn Carlier T, Badloe FMS, Ring J, Gutermuth J, Kortekaas Krohn I. Autoreactive T cells and their role in atopic dermatitis. J Autoimmun 2021;120:102634. [PMID: 33892348 DOI: 10.1016/j.jaut.2021.102634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dubin C, Glickman JW, Del Duca E, Chennareddy S, Han J, Dahabreh D, Estrada YD, Zhang N, Kimmel GW, Singer G, Chowdhury M, Zheng AY, Angelov M, Gay-Mimbrera J, Ruano Ruiz J, Krueger JG, Pavel AB, Guttman-Yassky E. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol 2021:S0190-9622(21)00999-3. [PMID: 34044102 DOI: 10.1016/j.jaad.2021.05.016] [Reference Citation Analysis]
5 Moon IJ, Yun MR, Yoon HK, Lee KH, Choi SY, Lee WJ, Chang SE, Won CH. Treatment of atopic dermatitis using non-thermal atmospheric plasma in an animal model. Sci Rep 2021;11:16091. [PMID: 34373514 DOI: 10.1038/s41598-021-95471-z] [Reference Citation Analysis]
6 Siegels D, Heratizadeh A, Abraham S, Binnmyr J, Brockow K, Irvine AD, Halken S, Mortz CG, Flohr C, Schmid-Grendelmeier P, Van der Poel LA, Muraro A, Weidinger S, Werfel T, Schmitt J; European Academy of Allergy, Clinical Immunology Atopic Dermatitis Guideline group. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy 2021;76:1053-76. [PMID: 33074565 DOI: 10.1111/all.14631] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
7 Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother 2019;15:2129-39. [PMID: 30785362 DOI: 10.1080/21645515.2019.1582403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
8 Chen BR, Hsu KT, Li TL, Chan YL, Wu CJ. Topical application of fucoidan derived from Cladosiphon okamuranus alleviates atopic dermatitis symptoms through immunomodulation. Int Immunopharmacol 2021;101:108362. [PMID: 34801417 DOI: 10.1016/j.intimp.2021.108362] [Reference Citation Analysis]
9 Kovalenko P, Davis JD, Li M, Rippley R, Ardeleanu M, Shumel B, Graham NMH, Pirozzi G, Kamal MA, DiCioccio AT. Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data. Clin Pharmacol Drug Dev 2020;9:756-67. [PMID: 32096596 DOI: 10.1002/cpdd.780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Brøgger P, Blom LH, Simonsen S, Thyssen JP, Skov L. Antagonism of the interleukin 4 receptor α promotes T H 1‐signalling among T cells from patients with atopic dermatitis after stimulation. Scand J Immunol 2019;91. [DOI: 10.1111/sji.12835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 D'Erme AM, Fidanzi C, Bagnoni G, Pardossi S, Manzo Margiotta F, Janowska A, Dini V, Romanelli M. Effect of dupilumab on genital condylomata: a case report. Sex Transm Infect 2021:sextrans-2021-055301. [PMID: 34740977 DOI: 10.1136/sextrans-2021-055301] [Reference Citation Analysis]
12 Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019;181:459-73. [PMID: 30851191 DOI: 10.1111/bjd.17869] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 34.3] [Reference Citation Analysis]
13 Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaçi D, Blauvelt A, Worm M, Corren J, Soong W, Lio P, Rossi AB, Lu Y, Chao J, Eckert L, Gadkari A, Hultsch T, Ruddy M, Mannent LP, Graham NMH, Pirozzi G, Chen Z, Ardeleanu M. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. J Allergy Clin Immunol Pract 2021;9:1212-1223.e6. [PMID: 33453450 DOI: 10.1016/j.jaip.2020.12.059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy 2020;50:5-14. [PMID: 31505066 DOI: 10.1111/cea.13491] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
15 Wu J, Del Duca E, Espino M, Gontzes A, Cueto I, Zhang N, Estrada YD, Pavel AB, Krueger JG, Guttman-Yassky E. RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing. Front Immunol 2020;11:597741. [PMID: 33329590 DOI: 10.3389/fimmu.2020.597741] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Hennies HC, Poumay Y. Skin Disease Models In Vitro and Inflammatory Mechanisms: Predictability for Drug Development. Handb Exp Pharmacol 2021;265:187-218. [PMID: 33387068 DOI: 10.1007/164_2020_428] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dębińska A. New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression. J Clin Med 2021;10:2506. [PMID: 34198894 DOI: 10.3390/jcm10112506] [Reference Citation Analysis]
18 Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong PY, O'Mahony L, Schwarze J, Warner A, Werfel T, Palomares O, Jutel M. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy 2021;76:988-1009. [PMID: 33538044 DOI: 10.1111/all.14690] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Glickman JW, Dubin C, Renert-Yuval Y, Dahabreh D, Kimmel GW, Auyeung K, Estrada YD, Singer G, Krueger JG, Pavel AB, Guttman-Yassky E. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol 2021;84:370-80. [PMID: 32376430 DOI: 10.1016/j.jaad.2020.04.138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
20 Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag 2020;16:1319-32. [PMID: 33408476 DOI: 10.2147/TCRM.S292504] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Patel N, Konda S, Lim HW. Dupilumab for the treatment of chronic actinic dermatitis. Photodermatol Photoimmunol Photomed 2020;36:398-400. [PMID: 32320500 DOI: 10.1111/phpp.12566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Diaz A, Tan K, He H, Xu H, Cueto I, Pavel A, Krueger J, Guttman‐yassky E. Keloid lesions show increased IL ‐4/ IL ‐13 signaling and respond to Th2‐targeting dupilumab therapy. J Eur Acad Dermatol Venereol 2020;34. [DOI: 10.1111/jdv.16097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
23 Furue K, Ulzii D, Tanaka Y, Ito T, Tsuji G, Kido‐nakahara M, Nakahara T, Furue M. Pathogenic implication of epidermal scratch injury in psoriasis and atopic dermatitis. J Dermatol 2020;47:979-88. [DOI: 10.1111/1346-8138.15507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
24 Ogg G. Natural killer cells get under your skin. Sci Transl Med 2020;12:eaba9181. [DOI: 10.1126/scitranslmed.aba9181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Tanczosova M, Arenberger P, Rychlik I, Arenbergerova M, Gkalpakiotis S. Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab. Dermatol Ther 2021;34:e14708. [PMID: 33368910 DOI: 10.1111/dth.14708] [Reference Citation Analysis]
26 Miyano T, Irvine AD, Tanaka RJ. Model-based meta-analysis to optimise S. aureus-targeted therapies for atopic dermatitis. JID Innovations 2022. [DOI: 10.1016/j.xjidi.2022.100110] [Reference Citation Analysis]
27 Chia SY, Wee LWY, Koh MJA. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective. Dermatol Ther 2021;34:e14933. [PMID: 33751751 DOI: 10.1111/dth.14933] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amin N, Ardeleanu M, Radin A, Shumel B, Ruddy M, Patel N, Pirozzi G, Mannent L, Graham NMH. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy 2021;51:915-31. [PMID: 34037993 DOI: 10.1111/cea.13954] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Andreasen T, Christensen M, Halling A, Egeberg A, Thyssen J. Placebo response in phase 2 and 3 trials of systemic and biological therapies for atopic dermatitis—a systematic review and meta‐analysis. J Eur Acad Dermatol Venereol 2020;34:1143-50. [DOI: 10.1111/jdv.16163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Braun C, Vocanson M, Nicolas JF, Nosbaum A. Physiopathologie de la dermatite atopique et des autres maladies atopiques : une approche globale est-elle possible ?: Pathophysiology of atopic dermatitis and other atopic diseases: is a global approach possible? Ann Dermatol Venereol 2020;147:11S4-11S11. [PMID: 33250137 DOI: 10.1016/S0151-9638(20)31082-6] [Reference Citation Analysis]
31 Quint T, Brunner PM, Sinz C, Steiner I, Ristl R, Vigl K, Kimeswenger S, Neubauer K, Pirkhammer D, Zikeli M, Hoetzenecker W, Reider N, Bangert C. Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis. J Clin Med 2020;9:E1241. [PMID: 32344789 DOI: 10.3390/jcm9041241] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
32 Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P, Ardeleanu M, Hultsch T, Guttman-Yassky E, Bissonnette R, Silverberg JI, Krueger J, Menter A, Graham NMH, Pirozzi G, Hamilton JD, Gallo RL. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. J Invest Dermatol 2020;140:191-202.e7. [PMID: 31252032 DOI: 10.1016/j.jid.2019.05.024] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
33 Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci 2020;21:E2867. [PMID: 32326002 DOI: 10.3390/ijms21082867] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 13.5] [Reference Citation Analysis]
34 Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, Hide M, Sher L, Hussain I, Chen Z, Khokhar FA, Beazley B, Ruddy M, Patel N, Graham NMH, Ardeleanu M, Shumel B. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol 2020;21:567-77. [PMID: 32557382 DOI: 10.1007/s40257-020-00527-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
35 Martinez-Cabriales SA, Kirchhof MG, Constantinescu CM, Murguia-Favela L, Ramien ML. Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020. Am J Clin Dermatol 2021;22:443-55. [PMID: 34076879 DOI: 10.1007/s40257-021-00607-6] [Reference Citation Analysis]
36 Worm M, Reese I, Ballmer-Weber B, Beyer K, Bischoff SC, Bohle B, Brockow K, Claßen M, Fischer PJ, Hamelmann E, Jappe U, Kleine-Tebbe J, Klimek L, Koletzko B, Lange L, Lau S, Lepp U, Mahler V, Nemat K, Raithel M, Saloga J, Schäfer C, Schnadt S, Schreiber J, Szépfalusi Z, Treudler R, Wagenmann M, Werfel T, Zuberbier T. Update of the S2k guideline on the management of IgE-mediated food allergies. Allergol Select 2021;5:195-243. [PMID: 34263109 DOI: 10.5414/ALX02257E] [Reference Citation Analysis]
37 Bakker DS, van der Wal MM, Heeb LE, Giovannone B, Asamoah M, Delemarre EM, Drylewicz J, Nierkens S, Boyman O, de Bruin-weller MS, Thijs JL, van Wijk F. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis. Journal of Investigative Dermatology 2021;141:1943-1953.e13. [DOI: 10.1016/j.jid.2021.01.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
38 Cristaudo A, Pigliacelli F, Sperati F, Orsini D, Cameli N, Morrone A, Mariano M. Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic dermatitis: An observational study. Skin Res Technol 2021;27:810-3. [PMID: 33651467 DOI: 10.1111/srt.13025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Bangert C, Rindler K, Krausgruber T, Alkon N, Thaler FM, Kurz H, Ayub T, Demirtas D, Fortelny N, Vorstandlechner V, Bauer WM, Quint T, Mildner M, Jonak C, Elbe-Bürger A, Griss J, Bock C, Brunner PM. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade. Sci Immunol 2021;6:eabe2749. [PMID: 33483337 DOI: 10.1126/sciimmunol.abe2749] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
40 Furue M. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. Int J Mol Sci 2020;21:E5382. [PMID: 32751111 DOI: 10.3390/ijms21155382] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
41 Lázaro-sastre M, García-sánchez A, Gómez-cardeñosa A, Dávila I. Dupilumab in Atopic Dermatitis. Curr Treat Options Allergy 2019;6:211-25. [DOI: 10.1007/s40521-019-00218-x] [Reference Citation Analysis]
42 Czarnowicki T, He H, Krueger JG, Guttman-yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. Journal of Allergy and Clinical Immunology 2019;143:1-11. [DOI: 10.1016/j.jaci.2018.10.032] [Cited by in Crossref: 148] [Cited by in F6Publishing: 145] [Article Influence: 49.3] [Reference Citation Analysis]
43 Bakker DS, Ariens LFM, Giovannone B, Hijnen D, Delemarre EM, Knol E, Nierkens S, de Bruin-Weller MS, Thijs JL, Drylewicz J. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Allergy 2020;75:3287-9. [PMID: 33305359 DOI: 10.1111/all.14492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
44 Boguniewicz M. Biologics for Atopic Dermatitis. Immunol Allergy Clin North Am 2020;40:593-607. [PMID: 33012322 DOI: 10.1016/j.iac.2020.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
45 Worm M, Francuzik W, Dölle S, Lange L, Alexiou A. Aktuelle Entwicklungen zur Therapie der Erdnussallergie. Allergo J 2021;30:30-9. [DOI: 10.1007/s15007-021-4774-0] [Reference Citation Analysis]
46 Lang CCV, Renert-Yuval Y, Del Duca E, Pavel AB, Wu J, Zhang N, Dubin C, Obi A, Chowdhoury M, Kim M, Estrada YD, Krueger JG, Kaderbhai H, Semango G, Schmid-Grendelmeier P, Brüggen MC, Masenga JE, Guttman-Yassky E. Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients. Ann Allergy Asthma Immunol 2021:S1081-1206(21)00330-6. [PMID: 33975024 DOI: 10.1016/j.anai.2021.04.023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol 2021;84:139-47. [PMID: 32822798 DOI: 10.1016/j.jaad.2020.08.051] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
48 Roesner LM, Bridgewood C, McGonagle D, Wittmann M. Dupilumab: An Opportunity to Unravel In Vivo Actions of IL-4 and IL-13 in Humans. J Invest Dermatol 2021;141:1879-81. [PMID: 34303467 DOI: 10.1016/j.jid.2021.02.007] [Reference Citation Analysis]
49 Russo F, Taddeucci P, Lazzeri L, Flori ML, Rubegni P. Efficacy of Dupilumab in two patients with severe and recalcitrant atopic dermatitis previously treated with extracorporeal photopheresis. Dermatol Ther 2020;33:e13284. [PMID: 32092216 DOI: 10.1111/dth.13284] [Reference Citation Analysis]
50 Furue K, Ito T, Tsuji G, Ulzii D, Vu YH, Kido-Nakahara M, Nakahara T, Furue M. The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology 2019;158:281-6. [PMID: 31509236 DOI: 10.1111/imm.13120] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
51 Baylet A, Vyumvuhore R, Laclaverie M, Marchand L, Mainzer C, Bordes S, Closs-Gonthier B, Delpy L. Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for atopic dermatitis (AD) treatment. Allergy Asthma Clin Immunol 2021;17:73. [PMID: 34281610 DOI: 10.1186/s13223-021-00574-x] [Reference Citation Analysis]
52 Leyva-Castillo JM, Das M, Kane J, Strakosha M, Singh S, Wong DSH, Horswill AR, Karasuyama H, Brombacher F, Miller LS, Geha RS. Basophil-derived IL-4 promotes cutaneous Staphylococcus aureus infection. JCI Insight 2021;6:e149953. [PMID: 34747366 DOI: 10.1172/jci.insight.149953] [Reference Citation Analysis]
53 Brar KK, Nicol NH, Boguniewicz M. Strategies for Successful Management of Severe Atopic Dermatitis. The Journal of Allergy and Clinical Immunology: In Practice 2019;7:1-16. [DOI: 10.1016/j.jaip.2018.10.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
54 Yang TB, Kim BS. Pruritus in allergy and immunology. J Allergy Clin Immunol 2019;144:353-60. [PMID: 31395149 DOI: 10.1016/j.jaci.2019.06.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
55 Pavel AB, Song T, Kim H, Del Duca E, Krueger JG, Dubin C, Peng X, Xu H, Zhang N, Estrada YD, Denis L, Rao N, Gupta S, Zammit DJ, Bissonnette R, Guttman-yassky E. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology 2019;144:1011-24. [DOI: 10.1016/j.jaci.2019.07.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
56 Schwartz C, Moran T, Saunders SP, Kaszlikowska A, Floudas A, Bom J, Nunez G, Iwakura Y, O'Neill L, Irvine AD, McKenzie ANJ, Ogg G, Walsh PT, Demengeot J, Fallon PG. Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by IL-1β. Allergy 2019;74:1920-33. [PMID: 30937919 DOI: 10.1111/all.13801] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
57 Luger T, Amagai M, Dreno B, Dagnelie MA, Liao W, Kabashima K, Schikowski T, Proksch E, Elias PM, Simon M, Simpson E, Grinich E, Schmuth M. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. J Dermatol Sci 2021;102:142-57. [PMID: 34116898 DOI: 10.1016/j.jdermsci.2021.04.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Spekhorst LS, Ariëns LFM, van der Schaft J, Bakker DS, Kamsteeg M, Oosting AJ, de Ridder I, Sloeserwij A, Romeijn GLE, de Graaf M, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry. Allergy 2020;75:2376-9. [PMID: 32302412 DOI: 10.1111/all.14324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
59 Strober B, Mallya UG, Yang M, Ganguli S, Gadkari A, Wang J, Sierka D, Delevry D, Kimball AB. Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study. JAMA Dermatol 2021. [PMID: 34910086 DOI: 10.1001/jamadermatol.2021.4778] [Reference Citation Analysis]
60 Ding M, Dong X, Sun YL, Sokolowska M, Akdis M, van de Veen W, Azkur AK, Azkur D, Akdis CA, Gao YD. Recent advances and developments in COVID-19 in the context of allergic diseases. Clin Transl Allergy 2021;11:e12065. [PMID: 34582102 DOI: 10.1002/clt2.12065] [Reference Citation Analysis]
61 Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, Purohit VS, Zielinski MA, Vlahos B, Estrada YD, Saint-cyr Proulx E, Ports WC, Guttman-yassky E. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial. Journal of Allergy and Clinical Immunology 2019;144:1274-89. [DOI: 10.1016/j.jaci.2019.06.047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
62 Miyano T, Irvine AD, Tanaka RJ. A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis. Allergy 2021. [PMID: 33894014 DOI: 10.1111/all.14870] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
63 Ferrucci S, Casazza G, Angileri L, Tavecchio S, Germiniasi F, Berti E, Marzano AV, Genovese G. Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience. J Clin Med 2020;9:E791. [PMID: 32183179 DOI: 10.3390/jcm9030791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
64 Eichenfield LF, Armstrong A, Guttman-Yassky E, Lio PA, Chen CC, Hines DM, McGuiness CB, Ganguli S, Delevry D, Sierka D, Mallya UG. Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset. Dermatol Ther (Heidelb) 2022. [PMID: 35543920 DOI: 10.1007/s13555-022-00731-z] [Reference Citation Analysis]
65 van der Schaft J, Thijs JL, de Bruin-weller MS, Balak DM. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next? Current Opinion in Allergy & Clinical Immunology 2019;19:341-9. [DOI: 10.1097/aci.0000000000000551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
66 Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J Allergy Clin Immunol Pract 2020;8:91-101. [PMID: 31474543 DOI: 10.1016/j.jaip.2019.06.044] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
67 Möbus L, Rodriguez E, Harder I, Stölzl D, Boraczynski N, Gerdes S, Kleinheinz A, Abraham S, Heratizadeh A, Handrick C, Haufe E, Werfel T, Schmitt J, Weidinger S; TREATgermany study group. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol 2021;147:213-23. [PMID: 32615169 DOI: 10.1016/j.jaci.2020.06.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
68 Steck O, Bertschi N, Luther F, Berg J, Winkel D, Holbro A, Schlapbach C. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol 2021;35:1331-7. [DOI: 10.1111/jdv.17001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
69 Olesen C, Holm J, Nørreslet L, Serup J, Thomsen S, Agner T. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol 2019;33:1562-8. [DOI: 10.1111/jdv.15609] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
70 Yang X, Kambe N, Takimoto-ito R, Kabashima K. Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. Pharmacology & Therapeutics 2021;224:107830. [DOI: 10.1016/j.pharmthera.2021.107830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Imai Y, Kusakabe M, Nagai M, Yasuda K, Yamanishi K. Dupilumab Effects on Innate Lymphoid Cell and Helper T Cell Populations in Patients with Atopic Dermatitis. JID Innov 2021;1:100003. [PMID: 34909707 DOI: 10.1016/j.xjidi.2021.100003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V, Zhang H, Chen Z, Chen C, Korotzer A, Sierka D, Fenton MC, Kaur M, Jalbert JJ. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol 2021;126:40-5. [PMID: 32739313 DOI: 10.1016/j.anai.2020.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
73 Silverberg JI, Simpson EL, Guttman-Yassky E, Cork MJ, de Bruin-Weller M, Yosipovitch G, Eckert L, Chen Z, Ardeleanu M, Shumel B, Hultsch T, Rossi AB, Hamilton JD, Orengo JM, Ruddy M, Graham NMH, Pirozzi G, Gadkari A. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. Dermatitis 2021;32:S81-91. [PMID: 33165005 DOI: 10.1097/DER.0000000000000698] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Renert-yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, Guttman-yassky E. Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council. Journal of Allergy and Clinical Immunology 2021;147:1174-1190.e1. [DOI: 10.1016/j.jaci.2021.01.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
75 Cochez P, Choteau M, Limaye N, Baeck M, Dumoutier L. Implication of T Helper Cytokines in Contact Dermatitis and Atopic Dermatitis. Curr Treat Options Allergy 2020;7:258-73. [DOI: 10.1007/s40521-020-00263-x] [Reference Citation Analysis]
76 Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. J Allergy Clin Immunol Pract 2021;9:1053-65. [PMID: 33685604 DOI: 10.1016/j.jaip.2020.11.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
77 Furue M, Ulzii D, Vu YH, Tsuji G, Kido-nakahara M, Nakahara T. Atopic Dermatitis and Type 2 Immune Deviation. Curr Treat Options Allergy 2019;6:200-10. [DOI: 10.1007/s40521-019-00219-w] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 [DOI: 10.1101/2020.08.28.272781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Yin H, Wang S, Gu C. Identification of Molecular Signatures in Mild Intrinsic Atopic Dermatitis by Bioinformatics Analysis. Ann Dermatol 2020;32:130-40. [PMID: 33911724 DOI: 10.5021/ad.2020.32.2.130] [Reference Citation Analysis]
80 Tuttle KL, Forman J, Beck LA. Novel systemic treatments in atopic dermatitis: Are there sex differences? Int J Womens Dermatol 2021;7:606-14. [PMID: 35024415 DOI: 10.1016/j.ijwd.2021.10.002] [Reference Citation Analysis]
81 Tameez Ud Din A, Malik I, Arshad D, Tameez Ud Din A. Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for? Cureus 2020;12:e7565. [PMID: 32382467 DOI: 10.7759/cureus.7565] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Harms M, Habib MMW, Nemska S, Nicolò A, Gilg A, Preising N, Sokkar P, Carmignani S, Raasholm M, Weidinger G, Kizilsavas G, Wagner M, Ständker L, Abadi AH, Jumaa H, Kirchhoff F, Frossard N, Sanchez-Garcia E, Münch J. An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation. Acta Pharm Sin B 2021;11:2694-708. [PMID: 34589390 DOI: 10.1016/j.apsb.2020.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
83 Min MS, Wu J, He H, Sanz-Cabanillas JL, Del Duca E, Zhang N, Renert-Yuval Y, Pavel AB, Lebwohl M, Guttman-Yassky E. Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. J Am Acad Dermatol 2020;83:63-70. [PMID: 31870914 DOI: 10.1016/j.jaad.2019.12.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
84 Jackson-Cowan L, Cole EF, Arbiser JL, Silverberg JI, Lawley LP. TH2 sensitization in the skin-gut-brain axis: How early-life Th2-mediated inflammation may negatively perpetuate developmental and psychologic abnormalities. Pediatr Dermatol 2021. [PMID: 34338364 DOI: 10.1111/pde.14657] [Reference Citation Analysis]
85 Agache I, Cojanu C, Laculiceanu A, Rogozea L. Critical Points on the Use of Biologicals in Allergic Diseases and Asthma. Allergy Asthma Immunol Res 2020;12:24-41. [PMID: 31743962 DOI: 10.4168/aair.2020.12.1.24] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
86 Baghoomian W, Na C, Simpson EL. New and Emerging Biologics for Atopic Dermatitis. Am J Clin Dermatol 2020;21:457-65. [PMID: 32323259 DOI: 10.1007/s40257-020-00515-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
87 Dhar S, De A, Srinivas SM. Real-World Effectiveness and Safety of Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Indian Patients: A Multi Centric Retrospective Study. Indian J Dermatol 2021;66:297-301. [PMID: 34446954 DOI: 10.4103/ijd.ijd_860_20] [Reference Citation Analysis]
88 He H, Bissonnette R, Wu J, Diaz A, Saint-cyr Proulx E, Maari C, Jack C, Louis M, Estrada Y, Krueger JG, Zhang N, Pavel AB, Guttman-yassky E. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. Journal of Allergy and Clinical Immunology 2021;147:199-212. [DOI: 10.1016/j.jaci.2020.05.048] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
89 Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J, Diaz A, Estrada YD, Canter T, Zhang N, Wagner A, Chamlin S, Krueger JG, Guttman-Yassky E, Paller AS. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol 2021;148:148-63. [PMID: 33453290 DOI: 10.1016/j.jaci.2021.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
90 He H, Olesen CM, Pavel AB, Clausen ML, Wu J, Estrada Y, Zhang N, Agner T, Guttman-Yassky E. Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers. Front Immunol 2020;11:1768. [PMID: 32849633 DOI: 10.3389/fimmu.2020.01768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
91 Glickman JW, Han J, Garcet S, Krueger JG, Pavel AB, Guttman-yassky E. Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures. The Journal of Allergy and Clinical Immunology: In Practice 2020;8:3622-3625.e19. [DOI: 10.1016/j.jaip.2020.07.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
92 Loman L, Diercks GFH, Schuttelaar MLA. Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab. Contact Dermatitis 2021;84:124-7. [PMID: 32864776 DOI: 10.1111/cod.13693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
93 Reiger M, Schwierzeck V, Traidl-Hoffmann C. [Atopic eczema and microbiome]. Hautarzt 2019;70:407-15. [PMID: 31111169 DOI: 10.1007/s00105-019-4424-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
94 Ayasse M, Lockshin B, Do BK, Kaiser R, Silverberg JI. A case report of uveitis secondary to dupilumab treatment for atopic dermatitis. JAAD Case Rep 2021;7:98-9. [PMID: 33364278 DOI: 10.1016/j.jdcr.2020.11.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Pavel AB, Glickman JW, Michels JR, Kim-Schulze S, Miller RL, Guttman-Yassky E. Th2/Th1 Cytokine Imbalance Is Associated With Higher COVID-19 Risk Mortality. Front Genet 2021;12:706902. [PMID: 34335703 DOI: 10.3389/fgene.2021.706902] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Furue M. Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis. J Clin Med 2020;9:E3741. [PMID: 33233866 DOI: 10.3390/jcm9113741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
97 Zhou B, Peng C, Li L, Liu R, Zhu L, Chen X, Li J. Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study. Front Med 2022;9:838030. [DOI: 10.3389/fmed.2022.838030] [Reference Citation Analysis]
98 Topal FA, Zuberbier T, Makris MP, Hofmann M. The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases. Curr Opin Allergy Clin Immunol 2020;20:367-73. [PMID: 32590505 DOI: 10.1097/ACI.0000000000000658] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
99 Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020;82:377-88. [PMID: 31374300 DOI: 10.1016/j.jaad.2019.07.074] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
100 Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T, Igarashi A, Imafuku S, Kawashima M, Ohtsuki M, Fujita H, Arima K, Takagi H, Chen Z, Shumel B, Ardeleanu M. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials. Br J Dermatol 2020;183:39-51. [PMID: 31564057 DOI: 10.1111/bjd.18565] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
101 Han X, Krempski JW, Nadeau K. Advances and novel developments in mechanisms of allergic inflammation. Allergy 2020;75:3100-11. [PMID: 33068299 DOI: 10.1111/all.14632] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
102 Pellefigues C. IgE Autoreactivity in Atopic Dermatitis: Paving the Road for Autoimmune Diseases? Antibodies (Basel) 2020;9:E47. [PMID: 32911788 DOI: 10.3390/antib9030047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
103 Freitas E, Guttman-Yassky E, Torres T. Tralokinumab for the Treatment of Atopic Dermatitis. Am J Clin Dermatol 2021;22:625-38. [PMID: 34155602 DOI: 10.1007/s40257-021-00613-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, Seo SJ, Khokhar FA, Vakil J, Xiao J, Marco AR, Levit NA, O'Malley JT, Shabbir A. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol 2022. [PMID: 35503163 DOI: 10.1007/s40257-022-00685-0] [Reference Citation Analysis]
105 Macias AE, Guaní-Guerra E. Transfer Factor: Myths and Facts. Arch Med Res 2020;51:613-22. [PMID: 32654883 DOI: 10.1016/j.arcmed.2020.06.016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol 2020;156:44-56. [PMID: 31693077 DOI: 10.1001/jamadermatol.2019.3336] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 44.5] [Reference Citation Analysis]
107 Pereyra-Rodriguez JJ, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, Ruiz-Villaverde R, Vilar-Palomo S, Armario-Hita JC. Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis. Life (Basel) 2021;11:927. [PMID: 34575076 DOI: 10.3390/life11090927] [Reference Citation Analysis]
108 Gupta J, Margolis DJ. Filaggrin gene mutations with special reference to atopic dermatitis. Curr Treat Options Allergy 2020;7:403-13. [PMID: 33585163 DOI: 10.1007/s40521-020-00271-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Gilhar A, Reich K, Keren A, Kabashima K, Steinhoff M, Paus R. Mouse models of atopic dermatitis: a critical reappraisal. Exp Dermatol 2021;30:319-36. [PMID: 33368555 DOI: 10.1111/exd.14270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
110 Guo CJ, Mack MR, Oetjen LK, Trier AM, Council ML, Pavel AB, Guttman-Yassky E, Kim BS, Liu Q. Kallikrein 7 Promotes Atopic Dermatitis-Associated Itch Independently of Skin Inflammation. J Invest Dermatol 2020;140:1244-1252.e4. [PMID: 31883963 DOI: 10.1016/j.jid.2019.10.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
111 Lee SJ, Kim SE, Shin KO, Park K, Lee SE. Dupilumab Therapy Improves Stratum Corneum Hydration and Skin Dysbiosis in Patients With Atopic Dermatitis. Allergy Asthma Immunol Res 2021;13:762-75. [PMID: 34486260 DOI: 10.4168/aair.2021.13.5.762] [Reference Citation Analysis]
112 Zhou H, Shi L, Ren Y, Tan X, Liu W, Liu Z. Applications of Human Skin Microbiota in the Cutaneous Disorders for Ecology-Based Therapy. Front Cell Infect Microbiol 2020;10:570261. [PMID: 33194808 DOI: 10.3389/fcimb.2020.570261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Bankova LG, Barrett NA. Epithelial cell function and remodeling in nasal polyposis. Ann Allergy Asthma Immunol 2020;124:333-41. [PMID: 32007569 DOI: 10.1016/j.anai.2020.01.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
114 Worm M, Francuzik W, Dölle-Bierke S, Alexiou A. Use of biologics in food allergy management. Allergol Select 2021;5:103-7. [PMID: 33634220 DOI: 10.5414/ALX02141E] [Reference Citation Analysis]
115 Xiao S, Lu Z, Steinhoff M, Li Y, Buhl T, Fischer M, Chen W, Cheng W, Zhu R, Yan X, Yang H, Liu Y, Dou Y, Wang W, Wang J, Meng J. Innate immune regulates cutaneous sensory IL-13 receptor alpha 2 to promote atopic dermatitis. Brain Behav Immun 2021;98:28-39. [PMID: 34391816 DOI: 10.1016/j.bbi.2021.08.211] [Reference Citation Analysis]
116 Yaneva M, Darlenski R. The link between atopic dermatitis and asthma- immunological imbalance and beyond. Asthma Res Pract 2021;7:16. [PMID: 34911576 DOI: 10.1186/s40733-021-00082-0] [Reference Citation Analysis]
117 Lefèvre-Utile A, Braun C, Haftek M, Aubin F. Five Functional Aspects of the Epidermal Barrier. Int J Mol Sci 2021;22:11676. [PMID: 34769105 DOI: 10.3390/ijms222111676] [Reference Citation Analysis]
118 Akdis CA, Arkwright PD, Brüggen MC, Busse W, Gadina M, Guttman-Yassky E, Kabashima K, Mitamura Y, Vian L, Wu J, Palomares O. Type 2 immunity in the skin and lungs. Allergy 2020;75:1582-605. [PMID: 32319104 DOI: 10.1111/all.14318] [Cited by in Crossref: 62] [Cited by in F6Publishing: 73] [Article Influence: 31.0] [Reference Citation Analysis]
119 Mommert S, Schaper JT, Schaper-Gerhardt K, Gutzmer R, Werfel T. Histamine Increases Th2 Cytokine-Induced CCL18 Expression in Human M2 Macrophages. Int J Mol Sci 2021;22:11648. [PMID: 34769080 DOI: 10.3390/ijms222111648] [Reference Citation Analysis]
120 Tanei R. Atopic Dermatitis in Older Adults: A Review of Treatment Options. Drugs Aging 2020;37:149-60. [PMID: 32086792 DOI: 10.1007/s40266-020-00750-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
121 Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol 2021;17:835-52. [PMID: 34106037 DOI: 10.1080/1744666X.2021.1940962] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Guttman-Yassky E, Diaz A, Pavel AB, Fernandes M, Lefferdink R, Erickson T, Canter T, Rangel S, Peng X, Li R, Estrada Y, Xu H, Krueger JG, Paller AS. Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis. JAMA Dermatol 2019;155:1358-70. [PMID: 31596431 DOI: 10.1001/jamadermatol.2019.2983] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 41.0] [Reference Citation Analysis]
123 Nakahara T, Izuhara K, Onozuka D, Nunomura S, Tamagawa-Mineoka R, Masuda K, Ichiyama S, Saeki H, Kabata Y, Abe R, Ohtsuki M, Kamiya K, Okano T, Miyagaki T, Ishiuji Y, Asahina A, Kawasaki H, Tanese K, Mitsui H, Kawamura T, Takeichi T, Akiyama M, Nishida E, Morita A, Tonomura K, Nakagawa Y, Sugawara K, Tateishi C, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Hide M, Aoki N, Sano S, Matsuda-Hirose H, Hatano Y, Takenaka M, Murota H, Katoh N, Furue M. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol. Medicine (Baltimore) 2020;99:e22043. [PMID: 32957324 DOI: 10.1097/MD.0000000000022043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
124 Mikhaylov D, Del Duca E, Olesen CM, He H, Wu J, Ungar B, Estrada Y, Zhang N, Chowdhury M, Clausen ML, Krueger JG, Pavel AB, Agner T, Guttman-Yassky E. Transcriptomic Profiling of Tape-Strips From Moderate to Severe Atopic Dermatitis Patients Treated With Dupilumab. Dermatitis 2021;32:S71-80. [PMID: 34405829 DOI: 10.1097/DER.0000000000000764] [Reference Citation Analysis]
125 Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, King B, Banerjee A, Banfield C, Cox LA, Dowty ME, Page K, Vincent MS, Zhang W, Zhu L, Peeva E. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol 2021:S0091-6749(21)01823-6. [PMID: 34863853 DOI: 10.1016/j.jaci.2021.10.036] [Reference Citation Analysis]
126 Zhang C, Chinnappan M, Prestwood CA, Edwards M, Artami M, Thompson BM, Eckert KM, Vale G, Zouboulis CC, McDonald JG, Harris-Tryon TA. Interleukins 4 and 13 drive lipid abnormalities in skin cells through regulation of sex steroid hormone synthesis. Proc Natl Acad Sci U S A 2021;118:e2100749118. [PMID: 34521750 DOI: 10.1073/pnas.2100749118] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Yu Y, Lin D, Cai X, Cui D, Fang R, Zhang W, Yu B, Wang X. Enhancement of Chemokine mRNA Expression by Toll-Like Receptor 2 Stimulation in Human Peripheral Blood Mononuclear Cells of Patients with Atopic Dermatitis. Biomed Res Int 2020;2020:1497175. [PMID: 32280674 DOI: 10.1155/2020/1497175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 He H, Del Duca E, Diaz A, Kim HJ, Gay-mimbrera J, Zhang N, Wu J, Beaziz J, Estrada Y, Krueger JG, Pavel AB, Ruano J, Guttman-yassky E. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities. Journal of Allergy and Clinical Immunology 2021;147:1369-80. [DOI: 10.1016/j.jaci.2020.08.041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Joshi TP, Anvari S, Gupta MR, Davis CM, Hajjar J. Case Report: Dupilumab Successfully Controls Severe Eczema in a Child With Elevated IgE Levels and Recurrent Skin Infections. Front Pediatr 2021;9:646997. [PMID: 34660469 DOI: 10.3389/fped.2021.646997] [Reference Citation Analysis]
130 Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, Kamsteeg M, Giovannone B, Drylewicz J, van Amerongen CCA, Delemarre EM, Knol EF, van Wijk F, Nierkens S, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. Allergy 2020;75:116-26. [PMID: 31593343 DOI: 10.1111/all.14080] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
131 Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, Shumel B, Khokhar FA, Hultsch T, Rizova E, Rossi AB, Graham NMH, Pirozzi G, Lu Y, Ardeleanu M. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 2020;182:1120-35. [PMID: 31407311 DOI: 10.1111/bjd.18434] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
132 Damask CC, Ryan MW, Casale TB, Castro M, Franzese CB, Lee SE, Levy JM, Lin SY, Lio PA, Peters AT, Platt MP, White AA. Targeted Molecular Therapies in Allergy and Rhinology. Otolaryngol Head Neck Surg 2021;164:S1-S21. [PMID: 33138725 DOI: 10.1177/0194599820965233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
133 Russo F, Flori ML, Gola M, Milanesi N. Severe Adult Atopic Dermatitis: Clinical Challenges. Dermatitis 2020;31:e48-9. [DOI: 10.1097/der.0000000000000592] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
134 Ruiz‐villaverde R, Dominguez‐cruz J, Armario‐hita JC, Martinez‐pilar L, Alcantara‐luna S, Pereyra‐rodriguez JJ. Fifty‐two week follow‐up safety and effectiveness results of dupilumab treatment of moderate‐to‐severe atopic dermatitis from a retrospective, multicentric series. Dermatologic Therapy 2019. [DOI: 10.1111/dth.12931] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
135 Charvet E, Bourrat E, Hickman G, Donadieu J, Bellanné-Chantelot C, Jachiet M, Bouaziz JD, Bagot M, Cassius C. Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant. Clin Exp Dermatol 2021. [PMID: 33864281 DOI: 10.1111/ced.14686] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Renert-Yuval Y, Guttman-Yassky E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. Ann Allergy Asthma Immunol 2020;124:28-35. [PMID: 31622669 DOI: 10.1016/j.anai.2019.10.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 15.7] [Reference Citation Analysis]
137 Glickman JW, Dubin C, Han J, Dahabreh D, Garcet S, Krueger JG, Pavel AB, Guttman-yassky E. Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients. Journal of Allergy and Clinical Immunology 2020;145:1285-8. [DOI: 10.1016/j.jaci.2020.01.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
138 Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, Pontes DS, Silverberg JI, Choi J, Pro B, Pincus LB, Guitart J, Zhou XA. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol 2020;83:197-9. [PMID: 32229275 DOI: 10.1016/j.jaad.2020.03.050] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
139 Kamata M, Tada Y. A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis. JID Innov 2021;1:100042. [PMID: 34909737 DOI: 10.1016/j.xjidi.2021.100042] [Reference Citation Analysis]
140 Nakatani-Kusakabe M, Yasuda K, Tomura M, Nagai M, Yamanishi K, Kuroda E, Kanazawa N, Imai Y. Monitoring Cellular Movement with Photoconvertible Fluorescent Protein and Single-Cell RNA Sequencing Reveals Cutaneous Group 2 Innate Lymphoid Cell Subtypes, Circulating ILC2 and Skin-Resident ILC2. JID Innov 2021;1:100035. [PMID: 34909732 DOI: 10.1016/j.xjidi.2021.100035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Furue M, Ulzii D, Nakahara T, Tsuji G, Furue K, Hashimoto-hachiya A, Kido-nakahara M. Implications of IL-13Rα2 in atopic skin inflammation. Allergology International 2020;69:412-6. [DOI: 10.1016/j.alit.2020.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
142 Guttman-Yassky E, Gallo RL, Pavel AB, Nakatsuji T, Li R, Zhang N, Messersmith E, Maeda-Chubachi T. A Nitric Oxide-Releasing Topical Medication as a Potential Treatment Option for Atopic Dermatitis through Antimicrobial and Anti-Inflammatory Activity. J Invest Dermatol 2020;140:2531-2535.e2. [PMID: 32428543 DOI: 10.1016/j.jid.2020.04.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
143 Olesen CM, Ingham AC, Thomsen SF, Clausen ML, Andersen PS, Edslev SM, Yüksel YT, Guttman-Yassky E, Agner T. Changes in Skin and Nasal Microbiome and Staphylococcal Species Following Treatment of Atopic Dermatitis with Dupilumab. Microorganisms 2021;9:1487. [PMID: 34361924 DOI: 10.3390/microorganisms9071487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Wang Y, Wan Z, Jin R, Xu T, Ouyang Y, Wang B, Ruan G, Bai X. Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. International Immunopharmacology 2022;105:108517. [DOI: 10.1016/j.intimp.2022.108517] [Reference Citation Analysis]
145 Tubau C, Puig L. IL-13 antagonists in the treatment of atopic dermatitis. Immunotherapy 2021;13:327-44. [PMID: 33430628 DOI: 10.2217/imt-2020-0253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Ungar B, Pavel AB, Li R, Kimmel G, Nia J, Hashim P, Kim HJ, Chima M, Vekaria AS, Estrada Y, Xu H, Peng X, Singer GK, Baum D, Mansouri Y, Taliercio M, Guttman-yassky E. Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis. Journal of Allergy and Clinical Immunology 2021;147:394-7. [DOI: 10.1016/j.jaci.2020.04.055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
147 Campione E, Lanna C, Diluvio L, Cannizzaro MV, Grelli S, Galluzzo M, Talamonti M, Annicchiarico-Petruzzelli M, Mancini M, Melino G, Candi E, Schiavone G, Wang Y, Shi Y, Bianchi L. Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. Cell Cycle 2020;19:257-67. [PMID: 31905036 DOI: 10.1080/15384101.2019.1707455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
148 Beck LA, Silverberg JI, Simpson EL, Yosipovitch G, Eckert L, Guillemin I, Chen Z, Ardeleanu M, Plaum S, Graham N, Ruddy M, Pirozzi G, Gadkari A. Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials. J Eur Acad Dermatol Venereol 2021;35:e130-3. [PMID: 32789996 DOI: 10.1111/jdv.16865] [Reference Citation Analysis]
149 Di Filippo P, Russo D, Attanasi M, Di Pillo S, Chiarelli F. Immunological Targets of Biologic Drugs in Allergic Skin Diseases in Children. Biomedicines 2021;9:1615. [PMID: 34829844 DOI: 10.3390/biomedicines9111615] [Reference Citation Analysis]
150 Toncic RJ, Jakasa I, Hadzavdic SL, Goorden SM, Vlugt KJG, Stet FS, Balic A, Petkovic M, Pavicic B, Zuzul K, Marinovic B, Kezic S. Altered Levels of Sphingosine, Sphinganine and Their Ceramides in Atopic Dermatitis Are Related to Skin Barrier Function, Disease Severity and Local Cytokine Milieu. Int J Mol Sci 2020;21:E1958. [PMID: 32183011 DOI: 10.3390/ijms21061958] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
151 Kim M, Mikhaylov D, Rangel SM, Pavel AB, He H, Renert-Yuval Y, Del Duca E, Malik K, Huynh T, Ibler E, Sun M, Zhang N, Estrada Y, Krueger J, Paller AS, Guttman-Yassky E. Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures. J Invest Dermatol 2022:S0022-202X(22)00269-X. [PMID: 35421402 DOI: 10.1016/j.jid.2022.03.022] [Reference Citation Analysis]
152 Voorberg AN, Niehues H, Oosterhaven JAF, Romeijn GLE, van Vlijmen-Willems IMJJ, van Erp PEJ, Ederveen THA, Zeeuwen PLJM, Schuttelaar MLA. Vesicular hand eczema transcriptome analysis provides insights into its pathophysiology. Exp Dermatol 2021. [PMID: 34252224 DOI: 10.1111/exd.14428] [Reference Citation Analysis]
153 Izuhara K, Nunomura S, Nanri Y, Ono J, Takai M, Kawaguchi A. Periostin: An emerging biomarker for allergic diseases. Allergy 2019;74:2116-28. [DOI: 10.1111/all.13814] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
154 Fölster-Holst R, Torrelo A, Das K, Murrell DF, Patil A, Rahmat Pour Rokni G, Grabbe S, Staubach P, Sohn A, Goldust M. Biological medication in atopic dermatitis. Expert Opin Biol Ther 2022;:1-7. [PMID: 34991429 DOI: 10.1080/14712598.2022.2026920] [Reference Citation Analysis]
155 Pavel AB, Renert-Yuval Y, Wu J, Del Duca E, Diaz A, Lefferdink R, Fang MM, Canter T, Rangel SM, Zhang N, Krueger JG, Paller AS, Guttman-Yassky E. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy 2021;76:314-25. [PMID: 32639640 DOI: 10.1111/all.14490] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
156 Nakahara T, Kido‐nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. J Dermatol 2021;48:130-9. [DOI: 10.1111/1346-8138.15664] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
157 Patrick GJ, Archer NK, Miller LS. Which Way Do We Go? Complex Interactions in Atopic Dermatitis Pathogenesis. J Invest Dermatol 2021;141:274-84. [PMID: 32943210 DOI: 10.1016/j.jid.2020.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
158 Lam M, Zhu JW, Maqbool T, Adam G, Tadrous M, Rochon P, Drucker AM. Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis: A Systematic Review. JAMA Dermatol 2020;156:1240. [DOI: 10.1001/jamadermatol.2020.2940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
159 Armario‐hita J, Pereyra‐rodriguez J, Silvestre J, Ruiz‐villaverde R, Valero A, Izu‐belloso R, Jáuregui‐presa I, Curto‐barredo L, Figueras‐nart I, Herranz‐pinto P, Herraez‐herrera L, Ortiz‐de‐frutos F, Martinez‐pilar L, Sastre J, Serra‐baldrich E. Treatment of moderate‐to‐severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol 2019;181:1072-4. [DOI: 10.1111/bjd.18041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
160 Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev 2020;9:CD013206. [PMID: 32927498 DOI: 10.1002/14651858.CD013206.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
161 Yoshida T, Beck LA, De Benedetto A. Skin barrier defects in atopic dermatitis: From old idea to new opportunity. Allergol Int 2021:S1323-8930(21)00145-3. [PMID: 34916117 DOI: 10.1016/j.alit.2021.11.006] [Reference Citation Analysis]
162 Mizukawa Y, Sato Y, Ohyama M, Shiohara T. Restoration of sweating disturbance in atopic dermatitis treated with dupilumab. J Dermatol Sci 2020;100:79-81. [PMID: 32900571 DOI: 10.1016/j.jdermsci.2020.08.007] [Reference Citation Analysis]
163 Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, Peng X, Wen HC, Govas P, Gudi G, Ca V, Fang H, Salhi Y, Back J, Reddy V, Bissonnette R, Maari C, Grossman F, Wolff G. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 2019;144:482-493.e7. [PMID: 30738171 DOI: 10.1016/j.jaci.2018.11.053] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 19.7] [Reference Citation Analysis]
164 Ferrucci S, Romagnuolo M, Maronese CA, Germiniasi F, Tavecchio S, Angileri L, Casazza G, Marzano AV, Genovese G. Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis. Ther Adv Chronic Dis 2021;12:20406223211058332. [PMID: 34900210 DOI: 10.1177/20406223211058332] [Reference Citation Analysis]
165 Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, Rossi AB. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. JID Innovations 2022. [DOI: 10.1016/j.xjidi.2022.100131] [Reference Citation Analysis]
166 Russo F, Milanesi N, Cartocci A, Bruzziches F, Tronconi G, Lazzeri L, D'erme AM, Bagnoni G, Gola M, Cinotti E, Rubegni P, Flori ML. Dupilumab in Elderly Patients With Severe Atopic Dermatitis. Dermatitis 2021;32:S24-7. [PMID: 33332865 DOI: 10.1097/DER.0000000000000686] [Reference Citation Analysis]
167 Lefèvre-Utile A, Saichi M, Oláh P, Delord M, Homey B, Soumelis V; MAARS consortium. Transcriptome-based identification of novel endotypes in adult atopic dermatitis. Allergy 2021. [PMID: 34689335 DOI: 10.1111/all.15150] [Reference Citation Analysis]
168 Bohner A, Topham C, Strunck J, Haynes D, Brazil M, Clements J, Simpson E, Chamberlain W. Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up. Cornea 2021;40:584-9. [PMID: 32826648 DOI: 10.1097/ICO.0000000000002461] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
169 Hübenthal M, Löscher BS, Erdmann J, Franke A, Gola D, König IR, Emmert H. Current Developments of Clinical Sequencing and the Clinical Utility of Polygenic Risk Scores in Inflammatory Diseases. Front Immunol 2020;11:577677. [PMID: 33633722 DOI: 10.3389/fimmu.2020.577677] [Reference Citation Analysis]
170 Ahn J, Grinich EE, Choi Y, Guttman-Yassky E, Simpson EL. Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients. J Allergy Clin Immunol Pract 2021;9:1449-60. [PMID: 33838838 DOI: 10.1016/j.jaip.2021.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Jang DH, Heo SJ, Kook HD, Lee DH, Jung HJ, Park MY, Ahn J. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world. Sci Rep 2021;11:23539. [PMID: 34876623 DOI: 10.1038/s41598-021-02950-4] [Reference Citation Analysis]
172 Shimodaira Y, Takahashi S, Iijima K. Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report. BMC Gastroenterol 2021;21:207. [PMID: 33964871 DOI: 10.1186/s12876-021-01803-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Hashimoto T, Mishra SK, Olivry T, Yosipovitch G. Periostin, an Emerging Player in Itch Sensation. J Invest Dermatol 2021:S0022-202X(21)01116-7. [PMID: 34023128 DOI: 10.1016/j.jid.2021.03.009] [Reference Citation Analysis]
174 Villani AP, Pavel AB, Wu J, Fernandes M, Maari C, Saint-Cyr Proulx E, Jack C, Glickman J, Choi S, He H, Ungar B, Estrada Y, Kameyama N, Zhang N, Gonzales J, Tardif JC, Krueger JG, Bissonnette R, Guttman-Yassky E. Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. Allergy 2021. [PMID: 33866573 DOI: 10.1111/all.14859] [Reference Citation Analysis]
175 Yüksel YT, Nørreslet LB, Thyssen JP. Allergic Contact Dermatitis in Patients with Atopic Dermatitis. Curr Derm Rep 2021;10:67-76. [DOI: 10.1007/s13671-021-00335-4] [Reference Citation Analysis]
176 Ashbaugh AG, Murase EM, Raffi J, Botto N, Murase JE. Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing. Dermatitis 2022;33:51-61. [PMID: 35029349 DOI: 10.1097/DER.0000000000000801] [Reference Citation Analysis]
177 Glickman JW, Dubin C, Dahabreh D, Han J, Del Duca E, Estrada YD, Zhang N, Kimmel GW, Singer G, Krueger JG, Pavel AB, Guttman-Yassky E. An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. Allergy 2021. [PMID: 33721346 DOI: 10.1111/all.14814] [Reference Citation Analysis]
178 Florian P, Flechsenhar KR, Bartnik E, Ding‐pfennigdorff D, Herrmann M, Bryce PJ, Nestle FO. Translational drug discovery and development with the use of tissue‐relevant biomarkers: Towards more physiological relevance and better prediction of clinical efficacy. Exp Dermatol 2019;29:4-14. [DOI: 10.1111/exd.13942] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
179 Calzavara-Pinton P, Belloni Fortina A, Bonamonte D, Marseglia GL, Miraglia Del Giudice M, Musarra A, Nettis E, Neri I, Patruno C, Stingeni L, Peris K; RADAR Group. Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP). Ital J Dermatol Venerol 2021;156:184-97. [PMID: 32438781 DOI: 10.23736/S2784-8671.20.06654-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
180 Uchida H, Kamata M, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Tada Y. Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting. J Am Acad Dermatol 2020;82:1247-9. [PMID: 31884090 DOI: 10.1016/j.jaad.2019.12.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
181 Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD, Takahashi Y, Hasegawa S, Ming JE, DiCioccio AT, Li Y, Kovalenko P, Lu Q, Ortemann-Renon C, Ardeleanu M, Swanson BN. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clin Pharmacol Drug Dev 2020;9:742-55. [PMID: 32348036 DOI: 10.1002/cpdd.798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
182 Ferastraoaru D, Bax HJ, Bergmann C, Capron M, Castells M, Dombrowicz D, Fiebiger E, Gould HJ, Hartmann K, Jappe U, Jordakieva G, Josephs DH, Levi-Schaffer F, Mahler V, Poli A, Rosenstreich D, Roth-Walter F, Shamji M, Steveling-Klein EH, Turner MC, Untersmayr E, Karagiannis SN, Jensen-Jarolim E. AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clin Transl Allergy 2020;10:32. [PMID: 32695309 DOI: 10.1186/s13601-020-00335-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
183 Imamura S, Washio K, Mizuno M, Oda Y, Ogura K, Fukunaga A, Nishigori C. A case of atopic dermatitis with hypohidrosis improved after dupilumab treatment. J Cutan Immunol Allergy 2020;3:142-4. [DOI: 10.1002/cia2.12142] [Reference Citation Analysis]
184 Mikhaylov D, Del Duca E, Guttman-Yassky E. Proteomic signatures of inflammatory skin diseases: a focus on atopic dermatitis. Expert Rev Proteomics 2021;18:345-61. [PMID: 34033497 DOI: 10.1080/14789450.2021.1935247] [Reference Citation Analysis]
185 Schwingen J, Kaplan M, Kurschus FC. Review-Current Concepts in Inflammatory Skin Diseases Evolved by Transcriptome Analysis: In-Depth Analysis of Atopic Dermatitis and Psoriasis. Int J Mol Sci 2020;21:E699. [PMID: 31973112 DOI: 10.3390/ijms21030699] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
186 Corrêa MP, Areias LL, Correia-Silva RD, D'Ávila SCGP, Leopoldino AM, Greco KV, Gil CD. The Role of Galectin-9 as Mediator of Atopic Dermatitis: Effect on Keratinocytes. Cells 2021;10:947. [PMID: 33923930 DOI: 10.3390/cells10040947] [Reference Citation Analysis]
187 Kovalenko P, Kamal MA, Davis JD, Huniti N, Xu C, Bansal A, Shumel B, DiCioccio AT. Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data. Clin Pharmacol Drug Dev 2021. [PMID: 34159738 DOI: 10.1002/cpdd.986] [Reference Citation Analysis]
188 Paller AS, Beck LA, Blauvelt A, Siegfried EC, Cork MJ, Wollenberg A, Chen Z, Khokhar FA, Vakil J, Zhang A, Bansal A, Cyr SL. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data. Pediatr Dermatol 2022. [PMID: 35083774 DOI: 10.1111/pde.14909] [Reference Citation Analysis]
189 Fan J, Mishra SK. The emerging role of neuroimmune interactions in atopic dermatitis and itch. FEBS J 2021. [PMID: 33811449 DOI: 10.1111/febs.15860] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Kabashima K, Weidinger S. NK cells as a possible new player in atopic dermatitis. J Allergy Clin Immunol 2020;146:276-7. [PMID: 32439430 DOI: 10.1016/j.jaci.2020.04.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
191 Clayton K, Vallejo A, Sirvent S, Davies J, Porter G, Reading I, Lim F, Ardern‐jones M, Polak M. Machine learning applied to atopic dermatitis transcriptome reveals distinct therapy‐dependent modification of the keratinocyte immunophenotype*. Br J Dermatol 2021;184:913-22. [DOI: 10.1111/bjd.19431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
192 Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, Kamal MA, Davis JD, Sun X, Pirozzi G, Graham NMH, Gadkari A, Eckert L, Ruddy M, Bansal A. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol 2021;35:464-75. [PMID: 32893393 DOI: 10.1111/jdv.16928] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
193 Okoji UK, Agim NG, Heath CR. Features of Common Skin Disorders in Pediatric Patients with Skin of Color. Dermatol Clin 2022;40:83-93. [PMID: 34799038 DOI: 10.1016/j.det.2021.09.002] [Reference Citation Analysis]
194 Rohner MH, Thormann K, Cazzaniga S, Yousefi S, Simon HU, Schlapbach C, Simon D. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy 2021;76:1268-70. [PMID: 33210741 DOI: 10.1111/all.14664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
195 Khumalo J, Kirstein F, Scibiorek M, Hadebe S, Brombacher F. Therapeutic and prophylactic deletion of IL-4Ra-signaling ameliorates established ovalbumin induced allergic asthma. Allergy 2020;75:1347-60. [PMID: 31782803 DOI: 10.1111/all.14137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
196 Parker JJ, Sugarman JL, Silverberg NB, Gonzalez ME, Ramien ML, Teng JMC, Paller AS. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children. Pediatr Dermatol 2021;38:1500-5. [PMID: 34647354 DOI: 10.1111/pde.14820] [Reference Citation Analysis]
197 Tokura Y, Phadungsaksawasdi P, Ito T. Atopic dermatitis as Th2 disease revisited. J Cutan Immunol Allergy 2018;1:158-64. [DOI: 10.1002/cia2.12033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]